Form 4: AnaptysBio Director Ware Receives Equity Grants

AnaptysBio, Inc. Director J. Anthony Ware was granted 5,500 stock options and 4,000 restricted stock units on January 6, 2026.

Summary

• Director J. Anthony Ware of AnaptysBio, Inc. was granted equity awards on January 6, 2026.
• The grants include a stock option to purchase 5,500 shares of common stock at an exercise price of $43.91 per share.
• The stock option vests monthly over 12 months, commencing February 6, 2026, until fully vested, and expires on January 5, 2036.
• Additionally, 4,000 Restricted Stock Units (RSUs) were granted, representing a contingent right to receive common stock for no consideration.
• The RSUs will vest 100% on the date of AnaptysBio's 2027 annual meeting of shareholders.
• Both grants are subject to Mr. Ware's continued provision of service to the company on each vesting date.

Sentiment

Score: 7

Explanation: The grant of equity to a director is generally a positive signal, indicating continued commitment and alignment of interests. It's a routine compensation event, hence not extremely high, but certainly not negative.

Positives

• The grant of stock options and restricted stock units to a director aligns management's interests with shareholders, incentivizing long-term performance.
• Equity grants are a standard practice to attract and retain experienced board members, signaling continued commitment from a key director.

Negatives

• No negative information is present in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, but rather reports an insider equity grant.

Industry Context

The grant of equity awards to a director is a standard practice in the biotechnology industry to attract and retain talent, aligning their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• Equity compensation for directors, including stock options and restricted stock units, is a common practice across the biotechnology and pharmaceutical sectors, comparable to compensation structures at companies like Biogen Inc. or Amgen Inc.
• The vesting schedules, with monthly vesting for options and a cliff vest for RSUs tied to an annual meeting, are typical mechanisms used to ensure continued service and long-term commitment from board members.

Related Party Transactions

• Grant of 5,500 stock options to Director J. Anthony Ware with an exercise price of $43.91 per share.
• Grant of 4,000 Restricted Stock Units to Director J. Anthony Ware, representing a contingent right to receive common stock for no consideration.

Stakeholder Impact

• Shareholders: Potential future dilution from the exercise of options and settlement of RSUs, balanced by increased alignment of the director's interests with long-term shareholder value.
• Management: Strengthens the compensation package for a key director, potentially aiding retention and incentivizing long-term strategic focus.

Next Steps

• Continued provision of service by J. Anthony Ware to AnaptysBio, Inc. for vesting of equity awards.
• Monthly vesting of stock options commencing February 6, 2026.
• Vesting of Restricted Stock Units on the date of the Issuer's 2027 annual meeting of shareholders.

Key Dates

Recommendation

This Form 4 filing reports a routine equity grant to a director, which is a standard compensation practice and does not provide sufficient new information to alter an investment thesis. It indicates continued alignment of interests but does not present new fundamental data to warrant a 'buy' or 'sell' recommendation based solely on this filing.

Keywords

AnaptysBio, ANAB, Form 4, Insider Transaction, Stock Option, Restricted Stock Unit, Equity Grant, Director Compensation, J. Anthony Ware